The selection of a NAP1/BI/027 frequency of 50% considerably overestimates the burden of this strain of C. difficile. Current estimates of 22%-34% suggest that the prevalence of the BI strain is declining, with the United States likely experiencing a period of endemicity rather than epidemicity and outbreaks [3] [4] [5] .
We also question the use of utility weights for noninfectious diarrhea (range, 0.817-0.92, Table 1 [1]) as a proxy for C. difficile-associated diarrhea (CDAD). The values in Table 1 present a situation where the utility for nonsevere disease (0.88) is higher than the baseline utility for patients aged ≥65 years (0.84). If this were true, a patient aged ≥65 could potentially have improved quality of life when experiencing an episode of nonsevere CDAD. Other potential, more appropriate utility probabilities can be found in the Tufts Cost-Effectiveness Analysis Registry [6] . Using inaccurate or widely disparate utility values can significantly magnify errors in output [7] .
Finally, we draw attention to the independently conducted economic analysis of fidaxomicin vs vancomycin recently published by Stranges et al in Value in Health [8] . The two models share several efficacy and cost parameters, the inputs for which vary substantially. The significantly different inputs, combined with a more appropriate clinical scenario, produced a very different cost per quality-adjusted life-year of $67 576, substantially lower than Bartsch et al's $43.7 million [1, 8] .
We recognize the complexity of modeling treatment patterns in C. difficile infection; however, several inappropriate clinical and methodological assumptions significantly limit the value of this work. 
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